Climb Bio (NASDAQ:CLYM) Stock Rating Upgraded by Wall Street Zen

Climb Bio (NASDAQ:CLYM) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday.

A number of other equities research analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a research note on Saturday, September 27th. Robert W. Baird began coverage on shares of Climb Bio in a research note on Friday, August 15th. They set an “outperform” rating and a $9.00 price objective on the stock. Baird R W upgraded shares of Climb Bio to a “strong-buy” rating in a research note on Friday, August 15th. Finally, BTIG Research lifted their price objective on shares of Climb Bio from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Tuesday, September 30th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $9.25.

Climb Bio Stock Performance

CLYM stock opened at $1.65 on Monday. The stock has a market capitalization of $111.80 million, a price-to-earnings ratio of -2.36 and a beta of -0.07. Climb Bio has a 1 year low of $1.05 and a 1 year high of $5.47. The stock’s fifty day moving average is $2.05 and its two-hundred day moving average is $1.55.

Climb Bio (NASDAQ:CLYM) last posted its earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. As a group, analysts predict that Climb Bio will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Climb Bio

Institutional investors have recently bought and sold shares of the stock. Peapod Lane Capital LLC purchased a new position in Climb Bio during the 1st quarter valued at about $676,000. Allostery Investments LP purchased a new position in Climb Bio during the 1st quarter valued at about $299,000. RA Capital Management L.P. purchased a new position in Climb Bio during the 1st quarter valued at about $38,332,000. Bank of New York Mellon Corp purchased a new position in Climb Bio during the 1st quarter valued at about $79,000. Finally, TD Asset Management Inc purchased a new position in Climb Bio during the 1st quarter valued at about $109,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.